PharmExec Direct: Having trouble viewing the email? Click Here

In this ISSUE

Pharma in the News Spotlight

Financial Toxicity: Tracking a Growing Side Effect

BUSY CONGRESS UNLIKELY TO ACT ON DRUG PRICING LEGISLATION THIS FALL

Advertisement
Brexit
The UK’s Post-Brexit Life Sciences Strategy: Will It Deliver?
Reflector asks if the UK's newly announced post-Brexit life sciences strategy will be a springboard to addressing future EU ties in healthcare or just “more bluster”?
/Read more/
Advertisement
8th Clinical Quality Oversight Forum – October 11-13, Philadelphia
Join 150+ senior-level clinical quality, compliance and operations professionals to discuss strategies for ensuring trial integrity by effectively assessing, optimizing and managing the quality of clinical vendors and sites. Featured topics include ICH E6 R2, building a quality culture, inspection readiness, risk-based monitoring and auditing and more. Register by August 25 for maximum savings.
CLICK HERE FOR MORE INFORMATION AND TO REGISTER.
Brexit
UK Life Sciences Strategy: A Boon for Market Access?
Neil Grubert looks at the UK’s post-Brexit life sciences strategy’s measures for market access, a particular challenge in the UK market and key to its future success in the sector
/Read more/
Advertisement
How Can Scientific Dissemination Data Help Medical Affairs Adopt a more Strategic Role?
Live Webcast: Wednesday, September 20 at 11:00am EDT
Register now
Brexit
UK Life Sciences Strategy: Making Lemonade out of Lemons
Leela Barham casts her eye over the UK's plans for its life sciences industry in the post-Brexit world
/Read more/
Advertisement
Through the Patient's Eyes - Needs, Behaviors and the Science Behind it All
On Demand
Learn more
Strategy
Time to Disrupt SOPs?
Pharma companies still keep thousands of manufacturing procedures as text documents, an inefficient method that can lead to defective batches, recalls and warning letters. Why not use video for training, asks Boaz Sigelman
/Read more/
Adherence
Packaging for Patient Engagement
Funso Olufade discusses how solutions such as the new Adherence Package can help increase pharma–patient engagement
/Read more/
Advertisement
Outbound Virtual Engagement: A Brand Manager’s Tool for Covering White Space and Vacant Sales Territories
Sponsored by TrialCard
Download Whitepaper
Calendar
/ September 11–12: Bio/Pharma Product Launch Summit /
Boston, MA
/ September 14-15, 2017: Compliance Congress for Specialty Products /
Boston, MA
/ September 14–15: Risk Based Global Monitoring 2017 /
Barcelona, Spain
/ September 27–28: Finance and Accounting for Bioscience Companies /
New Brinswick, NJ
/ October 24–25: 12th Annual Value-Based Oncology Management /
Scottsdale, AZ
/ February 27–28, 2018: Speaker Programs 2018 /
Philadelphia, PA
Advertisement
RIM Best Practices: Unifying Data, Content & Regulatory Processes
Live Webcast: Thursday, September 14 at 1:00pm EDT
Register now
Industry update
//Novartis’s Chief Executive Officer, Joseph Jimenez, will step down at the end of January 2018. He will be replaced by Vasant (Vas) Narasimhan, currently global head of Drug Development and Chief Medical Officer. //Akari Therapeutics (New York, NY and London, UK) named Dr. David Horn Solomon as the company’s new Chief Executive Officer. //MedPharm (Durham, NC and Guildford) appointed Simon Redgrove as Chairman of the Board and Dr. Jeremy Drummond as Vice President of Business Development and member of the Executive Leadership Team. //Jesper Ericsson joined Symcel (Spånga, Sweden) as Chief Executive Officer. //
 
advertise with us / print subscribe / digital subscribe / visit pharmexec.com